- Home
- BTAI vs OTRK Comparison
BTAI vs OTRK Comparison
Compare BTAI & OTRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTAI
- OTRK
- Stock Information
- Founded
- BTAI 2017
- OTRK 2003
- Country
- BTAI United States
- OTRK United States
- Employees
- BTAI N/A
- OTRK N/A
- Industry
- BTAI Biotechnology: Pharmaceutical Preparations
- OTRK Misc Health and Biotechnology Services
- Sector
- BTAI Health Care
- OTRK Health Care
- Exchange
- BTAI Nasdaq
- OTRK Nasdaq
- Market Cap
- BTAI 6.6M
- OTRK 7.1M
- IPO Year
- BTAI 2018
- OTRK N/A
- Fundamental
- Price
- BTAI $2.13
- OTRK $1.59
- Analyst Decision
- BTAI Buy
- OTRK Strong Buy
- Analyst Count
- BTAI 4
- OTRK 1
- Target Price
- BTAI $37.00
- OTRK $45.00
- AVG Volume (30 Days)
- BTAI 279.4K
- OTRK 26.7K
- Earning Date
- BTAI 03-11-2025
- OTRK 04-15-2025
- Dividend Yield
- BTAI N/A
- OTRK N/A
- EPS Growth
- BTAI N/A
- OTRK N/A
- EPS
- BTAI N/A
- OTRK N/A
- Revenue
- BTAI $2,276,000.00
- OTRK $11,239,000.00
- Revenue This Year
- BTAI $105.36
- OTRK N/A
- Revenue Next Year
- BTAI $46.93
- OTRK $48.09
- P/E Ratio
- BTAI N/A
- OTRK N/A
- Revenue Growth
- BTAI 83.25
- OTRK N/A
- 52 Week Low
- BTAI $2.10
- OTRK $1.36
- 52 Week High
- BTAI $56.00
- OTRK $16.05
- Technical
- Relative Strength Index (RSI)
- BTAI 28.68
- OTRK 46.88
- Support Level
- BTAI $2.18
- OTRK $1.36
- Resistance Level
- BTAI $2.60
- OTRK $1.72
- Average True Range (ATR)
- BTAI 0.44
- OTRK 0.10
- MACD
- BTAI -0.08
- OTRK 0.00
- Stochastic Oscillator
- BTAI 0.94
- OTRK 59.49
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
About OTRK Ontrak Inc.
Ontrak Inc is an artificial intelligence (AI)-powered and technology-enabled behavioral healthcare company, whose mission is to help improve the health and save the lives of as many people as possible. The Company's technology-enabled platform utilizes claim-based analytics and predictive modeling to provide analytic insights throughout the delivery of our personalized care program. The company's integrated, technology-enabled OntrakTM solutions, a component of the PRE platform, are designed to treat members with behavioral conditions that cause chronic medical conditions such as diabetes, hypertension, coronary artery disease, COPD, and congestive heart failure.